A Comprehensive Review on the Development of Transdermal Patches for Sustained Release of Medication in Migraine Therapy
Main Article Content
Abstract
This extensive review study focuses on the developments and difficulties in the creation of transdermal patches for the treatment of migraines. Migraine is a common neurological condition marked by crippling headaches and frequently need early and effective treatment. A potential method for sustaining medication administration, transdermal patches provide regular dose and boost patient compliance. The composition of transdermal patches, the method of drug release, benefits, drawbacks, and potential applications in the treatment of migraines are all covered in this article.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Amiri P, Kazeminasab S, Nejadghaderi SA, Mohammadinasab R, Pourfathi H, Araj-Khodaei M, Sullman MJM, Kolahi AA, Safari S. Migraine: A Review on Its History, Global Epidemiology, Risk Factors, and Comorbidities. Front Neurol. 2022 Feb 23;12:800605. doi: 10.3389/fneur.2021.800605. PMID: 35281991; PMCID: PMC8904749.
II. Goadsby PJ. Chapter 422: migraine and other primary headache disorders. In: Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J, editors. Harrison's Principles of Internal Medicine 20/E (Vol1 & Vol2). New York, NY: McGraw-Hill Education; (2018).
III. Sacco S, Braschinsky M, Ducros A, Lampl C, Little P, van den Brink AM, et al.. European Headache Federation consensus on the definition of resistant and refractory migraine. J Headache Pain. (2020) 21:76. 10.1186/s10194-020-01130-5 [PMC free article] [PubMed]
IV. Straube A, Andreou A. Primary headaches during lifespan. J Headache Pain. (2019) 20:35. 10.1186/s10194-019-0985-0 [PMC free article] [PubMed]
V. Andreou AP, Edvinsson L. Mechanisms of migraine as a chronic evolutive condition. J Headache Pain. (2019) 20:117. 10.1186/s10194-019-1066-0 [PMC free article] [PubMed]
VI. Leonardi M, Raggi A. A narrative review on the burden of migraine: when the burden is the impact on people's life. J Headache Pain. (2019) 20:41. 10.1186/s10194-019-0993-0 [PMC free article] [PubMed]
VII. Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N, et al.. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. (2019) 18:459–80. 10.1016/S1474-4422(18)30499-X [PMC free article] [PubMed]
VIII. Safiri S, Pourfathi H, Eagan A, Mansournia MA, Khodayari MT, Sullman MJM, et al.. Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. PAIN. (2022) 163:e293–309. 10.1097/j.pain.0000000000002275
IX. Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ, Pozo-Rosich P, Martelletti P, Ducros A, Lantéri-Minet M, Braschinsky M, Del Rio MS, Daniel O, Özge A, Mammadbayli A, Arons M, Skorobogatykh K, Romanenko V, Terwindt GM, Paemeleire K, Sacco S, Reuter U, Lampl C, Schytz HW, Katsarava Z, Steiner TJ, Ashina M. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-514. doi: 10.1038/s41582-021-00509-5. Epub 2021 Jun 18. PMID: 34145431; PMCID: PMC8321897.
X. Bonafede M, Sapra S, Shah N, Tepper S, Cappell K, Desai P. Direct and indirect healthcare resource utilization and costs among migraine patients in the United States. Headache J Head Face Pain. (2018) 58:700–14. 10.1111/head.13275 [PubMed]
XI. Rapoport AM, Freitag F, Pearlman SH. Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine. CNS Drugs. 2010 Nov;24(11):929-40. doi: 10.2165/11317540-000000000-00000. PMID: 20932065.
XII. Sueiro AC, Mendes dos Santos É, Lacalendola Tundisi L, Masquetti Fava AL, Luna Silvério LA, Cedran Coco J, Ataide J, Paiva-Santos AC, Gava Mazzola P. Transdermal delivery systems for migraine treatment: A gap to explore. J Drug Deliv Sci Technol. 2022 Nov;77:103919. doi: 10.1016/j.jddst.2022.103919.
XIII. Abrams LS, Skee DM, Natarajan J, Wong FA, Anderson GD. Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites. Br J Clin Pharmacol. 2002;53:141–146.
XIV. Shakya P, Khwaja S. Transdermal patches. GPAT. 2012 Feb 7. Available
from:https://www.pharmatutor.org/articles/detail-information-on-transdermal-patches
XV. Keith AD. Polymer matrix considerations for transdermal devices, Drug Dev. Ind. Pharm 1983, 9, 605.
XVI. Pastore MN, Kalia YN, Horstmann M, Roberts MS. Transdermal patches: history, development and pharmacology. Br J Pharmacol. 2015 May;172(9):2179-209. doi: 10.1111/bph.13059. Epub 2015 Mar 18. PMID: 25560046; PMCID: PMC4403087.
XVII. Ahmed SR, Boucher AE, Manni A, Santen RJ, Bartholomew M. Transdermal testosterone therapy in treating male hypogonadism. J Clin Endocrinol Metab. 1988;66:546–551
XVIII. Ale I, Lachapelle J-M, Maibach HI. Skin tolerability associated with transdermal drug delivery systems: an overview. Adv Ther. 2009;26:920–935
XIX. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, McGrath JC, et al. The Concise Guide to PHARMACOLOGY 2013/14: Overview. Br J Pharmacol. 2013;170:1449–1458
XX. Anissimov YG, Roberts MS. Modelling dermal drug distribution after topical application in human. Pharm Res. 2011;28:2119–2129. [PubMed] [Google Scholar]
XXI. Arndts D, Arndts K. Pharmacokinetics and pharmacodynamics of transdermally administered clonidine. Eur J Clin Pharmacol. 1984;26:79–85
XXII. Baker RW, Heller J. Material selection for transdermal delivery systems; In: Hadgraft J, Guys RH, editors. Transdermal Drug Delivery: Development Issues and Research Initiatives. New York, Marcel Dekker Inc. 1989; 293-311.
XXIII. Guyot M, Fawaz F. Design and in vitro evaluation of adhesive matrix for transdermal delivery of propranolol , Int J Pharm 2000, 204, 171-182.
XXIV. STOWIC RESOURCES Ltd United Pharmaceutical Manufacturing Co Ltd.
https://patents.google.com/patent/US6871477B1/en
XXV. Verma D, Sharma HK, Budholiya P. Formulation, development and evaluation of transdermal patches of promethazine hydrochloride. Asian J Pharm Educ Res. 2019 Apr-Jun;8(2):52-60. ISSN 2278-7496.
XXVI. Rams-Baron M, Dolowy M, Potrzebowski MJ. Sumatriptan - from tablet to transdermal patch. Drug Dev Ind Pharm. 2015;41(12):1924-1929. https://doi.org/10.3109/03639045.2015.1027744
XXVII. Jain P, Jadhav KR, Kadam V. Transdermal patches: A complete review on transdermal drug delivery system. Int J Pharm Chem Sci. 2011;1(1):1-9. https://ijpcsonline.com/articles/transdermal-patches-a-complete-review-on-transdermal-drug-delivery-system.html
XXVIII. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261-1268. https://doi.org/10.1038/nbt.1504
XXIX. Mercadante S. Transdermal buprenorphine in cancer pain. Curr Pain Headache Rep. 2012;16(3):211-217. https://doi.org/10.1007/s11916-012-0242-4
XXX. Paudel KS, Hammell DC, Agu RU, Valiveti S, Stinchcomb AL, Crooks PA. Cannabidiol bioavailability after nasal and transdermal application: Effect of permeation enhancers. Drug Dev Ind Pharm. 2010;36(9):1088-1097. https://doi.org/10.3109/03639041003657295
XXXI. Knezevic I, Candido KD, Knezevic NN. Ergotamine: A review. Curr Pain Headache Rep. 2018;22(9):62. https://doi.org/10.1007/s11916-018-0715-
XXXII. Cilurzo F, Selmin F, Minghetti P, Adami M. Transdermal patches for sustained ketoprofen release: Preparation, characterization and in vitro/ex vivo evaluation. Eur J Pharm Sci. 2014;62:186-193. https://doi.org/10.1016/j.ejps.2014.04.012
XXXIII. Bhagav P, Medhe S, Kasture S. Formulation and evaluation of transdermal patches of metoclopramide hydrochloride. Der Pharmacia Lettre. 2012;4(4):1159-1170.
XXXIV. Alkilani AZ, McCrudden MT, Donnelly RF. Transdermal Drug Delivery: Innovative Pharmaceutical Developments Based on Disruption of the Barrier Properties of the stratum corneum. Pharmaceutics. 2015 Oct 22;7(4):438-70. doi: 10.3390/pharmaceutics7040438. PMID: 26506371; PMCID: PMC4695828.
XXXV. Anselmo A.C., Mitragotri S. An Overview of Clinical and Commercial Impact of Drug Delivery Systems. J. Control. Release. 2014;190:15–28. doi: 10.1016/j.jconrel.2014.03.053.
XXXVI. Han T., Das D.B. Potential of Combined Ultrasound and Microneedles for Enhanced Transdermal Drug Permeation: A Review. Eur. J. Pharm. Biopharm. 2015;89:312–328. doi: 10.1016/j.ejpb.2014.12.020.
XXXVII. Patel D, Chaudhary SA, Parmar B, Bhura N. Transdermal Drug Delivery System: A Review. The Pharma Innovation. 2012;1(4):66. Available from: www.thepharmajournal.com.
XXXVIII. Brambilla D., Luciani P., Leroux J. Breakthrough Discoveries in Drug Delivery Technologies: The Next 30 years. J. Control. Release. 2014;190:9–14. doi: 10.1016/j.jconrel.2014.03.056.
XXXIX. McCrudden M.T., Singh T.R.R., Migalska K., Donnelly R.F. Strategies for Enhanced Peptide and Protein Delivery. Ther. Deliv. 2013;4:593–614. doi: 10.4155/tde.13.31.
XL. Kretsos K., Kasting G.B. A Geometrical Model of Dermal Capillary Clearance. Math. Biosci. 2007;208:430–453. doi: 10.1016/j.mbs.2006.10.012.
XLI. Almoshari Y. Osmotic Pump Drug Delivery Systems-A Comprehensive Review. Pharmaceuticals (Basel). 2022 Nov 18;15(11):1430. doi: 10.3390/ph15111430. PMID: 36422560; PMCID: PMC9697821.
XLII. Arora A., Prausnitz M.R., Mitragotri S. Micro-Scale Devices for Transdermal Drug Delivery. Int. J. Pharm. 2008;364:227–236. doi: 10.1016/j.ijpharm.2008.08.032.
XLIII. Tuan-Mahmood T., McCrudden M.T., Torrisi B.M., McAlister E., Garland M.J., Singh T.R.R., Donnelly R.F. Microneedles for Intradermal and Transdermal Drug Delivery. Eur. J. Pharm. Sci. 2013;50:623–637. doi: 10.1016/j.ejps.2013.05.005.
XLIV. Prausnitz M.R., Langer R. Transdermal Drug Delivery. Nat. Biotechnol. 2008;26:1261–1268. doi: 10.1038/nbt.1504.
XLV. Liu X., Kruger P., Maibach H., Colditz P.B., Roberts M.S. Using Skin for Drug Delivery and Diagnosis in the Critically Ill. Adv. Drug Deliv. Rev. 2014;77:40–49. doi: 10.1016/j.addr.2014.10.004.
XLVI. Benson H.A., Watkinson A.C. Topical and Transdermal Drug Delivery: Principles and Practice. Wiley; Hoboken, NJ, USA: 2012.
XLVII. Gratieri T., Alberti I., Lapteva M., Kalia Y.N. Next Generation Intra-and Transdermal Therapeutic Systems: Using Non-and Minimally-Invasive Technologies to Increase Drug Delivery into and Across the Skin. Eur. J. Pharm. Sci. 2013;50:609–622. doi: 10.1016/j.ejps.2013.03.019.
XLVIII. Vikelis M, Spingos KC, Rapoport AM. The iontophoretic transdermal system formulation of sumatriptan as a new option in the acute treatment of migraine: a perspective. Ther Adv Neurol Disord. 2015 Jul;8(4):160-5. doi: 10.1177/1756285615585918. Erratum in: Ther Adv Neurol Disord. 2015 Nov;8(6):339. PMID: 26136843; PMCID: PMC4480530.
XLIX. Burstein R., Levy D., Jakubowski M. (2005) Effects of sensitization of trigeminovascular neurons to triptan therapy during migraine. Rev Neurol (Paris) 161: 658–660.
L. Derry C., Derry S., Moore R. (2012a) Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 15(2): CD008615.
LI. Derry C., Derry S., Moore R. (2012b) Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 15(2): CD009663.
LII. Dowson A., Bundy M., Salt R., Kilminster S. (2007) Patient preference for triptan formulations: a prospective study with zolmitriptan. Headache 47: 1144–1151.
LIII. useau E., Petricoul O., Moore K., Barrow A., Ibbotson T. (2002) Clinical pharmacokinetics of intranasal sumatriptan. Clin Pharmacokinet 41: 801–11.
LIV. Goldstein J, Pugach N, Smith T, Nett R, Angelov A, Pierce M. Acute anti-migraine efficacy and tolerability of Zelrix, a novel iontophoretic transdermal patch of sumatriptan. Cephalalgia. 2009;29(Suppl 1):20–20.
LV. Loder EW, Rayhill M, Burch RC. Safety Problems With a Transdermal Patch for Migraine: Lessons From the Development, Approval, and Marketing Process. Headache. 2018 Nov;58(10):1639-1657. doi: 10.1111/head.13424. Epub 2018 Oct 27. PMID: 30367818.
LVI. Paudel KS, Milewski M, Swadley CL, Brogden NK, Ghosh P, Stinchcomb AL. Challenges and opportunities in dermal/transdermal delivery. Ther Deliv. 2010 Jul;1(1):109-31. doi: 10.4155/tde.10.16. PMID: 21132122; PMCID: PMC2995530.
LVII. Samad A, Ullah Z, Alam MI, Wais M, Shams MS. Transdermal drug delivery system: patent reviews. Recent Pat Drug Deliv Formul. 2009;3(2):143–52
LVIII. Rizwan M, Aqil M, Talegaonkar S, Azeem A, Sultana Y, Ali A. Enhanced transdermal drug delivery techniques: an extensive review of patents. Recent Pat Drug Deliv Formul. 2009;3(2):105–124.
LIX. Cevc G, Vierl U. Nanotechnology and the transdermal route: A state of the art review and critical appraisal. J Control Release. 2010 Feb 15;141(3):277-299. doi: 10.1016/j.jconrel.2009.10.016.
LX. Grammatikopoulou MG, Gkiouras K, Dardiotis E, Zafiriou E, Tsigalou C, Bogdanos DP. Peeking into the future: Transdermal patches for the delivery of micronutrient supplements. Metabolism Open. 2021 Sep;11:100109
LXI. Rapoport A., Freitag F., Pearlman S. (2010) Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine. CNS Drugs 24: 929–940.
LXII. Mdanda S, Ubanako P, Kondiah PPD, Kumar P, Choonara YE. Recent Advances in Microneedle Platforms for Transdermal Drug Delivery Technologies. Polymers (Basel). 2021 Jul 22;13(15):2405. doi: 10.3390/polym13152405. PMID: 34372008; PMCID: PMC8348894.
LXIII. He J, Zhang Y, Yu X, Xu C. Wearable patches for transdermal drug delivery. Acta Pharm Sin B. 2023 Jun;13(6):2298-2309. doi: 10.1016/j.apsb.2023.05.009.
LXIV. Economidou SN, Lamprou DA, Douroumis D. 3D printing applications for transdermal drug delivery. Int J Pharm. 2018 Jun 15;544(2):415-424. doi: 10.1016/j.ijpharm.2018.01.031. Epub 2018 Jan 20. PMID: 29355656.
LXV. Kang G, Kim S, Yang H, Jang M, Chiang L, Baek JH, Ryu JH, Choi GW, Jung H. Combinatorial application of dissolving microneedle patch and cream for improvement of skin wrinkles, dermal density, elasticity, and hydration. J Cosmet Dermatol. 2019 Aug;18(4):1083-1091. doi: 10.1111/jocd.12807. Epub 2018 Oct 29. PMID: 30375189.
LXVI. Al Hanbali OA, Khan HMS, Sarfraz M, Arafat M, Ijaz S, Hameed A. Transdermal patches: Design and current approaches to painless drug delivery. Acta Pharm. 2019 Jun 1;69(2):197-215. doi: 10.2478/acph-2019-0016. PMID: 31259729.
LXVII. Melnikov MY. The Current Evidence Levels for Biofeedback and Neurofeedback Interventions in Treating Depression: A Narrative Review. Neural Plast. 2021 Feb 4;2021:8878857. doi: 10.1155/2021/8878857. PMID: 33613671; PMCID: PMC7878101.
LXVIII. Tyler WJ, Boasso AM, Mortimore HM, Silva RS, Charlesworth JD, Marlin MA, Aebersold K, Aven L, Wetmore DZ, Pal SK. Transdermal neuromodulation of noradrenergic activity suppresses psychophysiological and biochemical stress responses in humans. Sci Rep. 2015 Sep 10;5:13865. doi: 10.1038/srep13865. PMID: 26353920; PMCID: PMC4564766.